Curated News
By: NewsRamp Editorial Staff
July 15, 2026

Nuvectis Pharma Raises $100M in Public Offering to Advance Pipeline

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Nuvectis Pharma raised $100M to advance its pipeline, potentially gaining a first-mover advantage in complement and oncology therapies.
  • Nuvectis priced a public offering of 5M shares at $20 each, with net proceeds funding NXP100, NXP200, and NXP900 development.
  • Nuvectis aims to develop innovative therapies for complement-mediated diseases and cancers, improving treatment options and patient lives.
  • Nuvectis NXP100 is a once-daily oral Factor B inhibitor with best-in-class potential for complement diseases requiring lifelong treatment.

Impact - Why it Matters

This news matters because Nuvectis Pharma's $100 million funding will accelerate the development of three promising drug candidates: NXP100 for complement-mediated diseases, NXP900 for SRC kinase-driven cancers, and NXP200 for BRAF-mutated tumors. For patients, this could mean faster access to novel therapies with best-in-class potential, including a once-daily oral treatment for chronic complement diseases. For investors, the offering signals strong confidence in Nuvectis's pipeline and provides capital to advance clinical trials, potentially leading to value creation if these programs succeed. The involvement of multiple underwriters also indicates broad market interest.

Summary

Nuvectis Pharma (NASDAQ: NVCT) has announced the pricing of its underwritten public offering of 5 million shares of common stock at $20.00 per share, with expected gross proceeds of approximately $100 million. The offering includes a 30-day option for underwriters to purchase up to an additional 750,000 shares. The company intends to use the net proceeds primarily to advance its pipeline programs, including NXP100, NXP200, and NXP900, as well as for general corporate purposes. Cantor is serving as the sole book-running manager, with several co-managers including H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners, and Titan Partners. The offering is expected to close on or about July 1, 2026.

Nuvectis Pharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies for immune complement-related conditions and oncology. Its pipeline includes NXP100, a complement Factor B inhibitor with best-in-class potential as a once-daily oral treatment for complement-mediated diseases. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases, targeting both catalytic and scaffolding functions. NXP200 is an oral, brain-penetrant BRAF inhibitor for BRAF V600X-mutated and non-V600-mutated solid tumors, including CNS cancer, colorectal cancer, melanoma, and non-small cell lung cancer. The company’s focus on these promising candidates underscores its commitment to addressing significant unmet medical needs.

InvestorWire (IW), a specialized communications platform within the Dynamic Brand Portfolio @ IBN, distributed the news release. IW provides advanced wire-grade press release syndication and a range of corporate communications solutions to help companies reach investors and the public. The offering details and pipeline updates are crucial for stakeholders tracking Nuvectis Pharma's progress.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nuvectis Pharma Raises $100M in Public Offering to Advance Pipeline

blockchain registration record for this content.